eltrombopag olamine (SB-497115-GR)
Phase 3Completed 0 watching 0 views this week๐ Rising
77
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Purpura, Thrombocytopaenic, Idiopathic
Conditions
Purpura, Thrombocytopaenic, Idiopathic
Trial Timeline
Jun 1, 2006 โ Jul 1, 2015
NCT ID
NCT00351468About eltrombopag olamine (SB-497115-GR)
eltrombopag olamine (SB-497115-GR) is a phase 3 stage product being developed by Novartis for Purpura, Thrombocytopaenic, Idiopathic. The current trial status is completed. This product is registered under clinical trial identifier NCT00351468. Target conditions include Purpura, Thrombocytopaenic, Idiopathic.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00351468 | Phase 3 | Completed |
Competing Products
20 competing products in Purpura, Thrombocytopaenic, Idiopathic